Clinical trials: psoriasis
Psoriasis
A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)
This study will evaluate the efficacy, tolerability, and effect on the quality of life of infliximab in adults with moderate-to-severe psoriasis who are resistant to etanercept after 12 weeks of treatment or have failed 24 weeks…
- Trial name
- TANGO (NCT00686595)
- Testing
- Infliximab
- Volunteers
- 48 people
- Sponsor
- Merck Sharp & Dohme LLC
Arthritis, Psoriatic
Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.
This clinical study will test the effects of a drug called apremilast in oligoarticular psoriatic arthritis with less than 5 years of disease duration.
- Trial name
- FOREMOST (NCT03747939)
- Testing
- Apremilast (CC-10004)
- Where
- 114 sites in United States, Austria and 9 more
- Volunteers
- 310 people
- Sponsor
- Amgen
Rheumatoid Arthritis, Ankylosing Spondylitis
Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients Who Are About to be Treated With Adalimumab
The purpose of this study is to assess whether or not adalimumab (Humira®) can influence pain medication in participants with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) with or without…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- NCT01273519
- Where
- 15 sites in Austria
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis, Moderate to Severe Plaque Psoriasis
A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis
This is a randomised, double-blind, multicentre clinical study to evaluate the efficacy, safety, tolerability, PK, and immunogenicity of SB17 compared to Stelara® in subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT04967508
- Testing
- Stelara® (Ustekinumab), SB17 (Proposed Ustekinumab Biosimilar)
- Where
- 32 sites in Czechia, Estonia and 6 more
- Volunteers
- 503 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Chronic Plaque Psoriasis
Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment
The objective of this study is to assess the efficacy and safety of adalimumab in combination with topical psoriasis treatment, calcipotriol/betamethasone, vs.
- Trial name
- BELIEVE (NCT00574249)
- Testing
- adalimumab, Calcipotriol/Betamethasone Ointment
- Where
- 131 sites in Austria, Belgium and 13 more
- Volunteers
- 730 people
- Sponsor
- Abbott
Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis
Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and Immunogenicity
Hulio is a monoclonal antibody currently approved as a biosimilar to European Union approved and United States (US)-Licensed Humira.
- Trial name
- NCT05637515
- Testing
- Humira 40 MG in Prefilled Syringe, Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled Syringe
- Where
- 36 sites in Bulgaria, Czechia and 2 more
- Volunteers
- 374 people
- Sponsor
- Biocon Biologics Inc.
Psoriasis
Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis
This is a phase I, open label, single group study that is being performed to assess the safety, tolerability, Pharmacokinetics (PK) , Pharmacogenomics (PGx) and efficacy of a single dose of spesolimab in adult patients with…
- Trial name
- NCT02978690
- Testing
- Spesolimab
- Where
- 6 sites in France, Japan and 4 more
- Volunteers
- 7 people
- Sponsor
- Boehringer Ingelheim
Psoriasis
A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy
The purpose of this study is to compare the efficacy and safety of subcutaneous (SC) risankizumab and oral FUMADERM provided as study medication in participants with moderate to severe plaque psoriasis who are naïve to and…
- Trial name
- NCT03255382
- Testing
- Fumaderm, risankizumab
- Where
- 23 sites in Germany
- Volunteers
- 120 people
- Sponsor
- AbbVie
Psoriasis
Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis
A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study.
- Trial name
- NCT02785185
- Testing
- IDP-122 Vehicle Lotion, IDP-122 Vehicle Cream, IDP-122 Lotion
- Where
- 13 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Psoriasis
A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis
This is an open-label, multi-center study to evaluate the efficacy and safety of VTAMA (tapinarof) cream, 1% in adults with intertriginous psoriasis
- Trial name
- NCT05680740
- Testing
- VTAMA® (tapinarof) Cream 1%
- Where
- 7 sites in United States
- Volunteers
- 34 people
- Sponsor
- Organon and Co
Plaque Psoriasis
A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to compare the efficacy and safety of ixekizumab to guselkumab in participants with moderate-to-severe plaque psoriasis.
- Trial name
- IXORA-R (NCT03573323)
- Testing
- Ixekizumab, Guselkumab
- Where
- 124 sites in United States, Canada and 1 more
- Volunteers
- 1,027 people
- Sponsor
- Eli Lilly and Company
Psoriasis Vulgaris
Safety and Efficacy of CD10367 in Psoriasis Vulgaris
This was an exploratory, single-center, investigator blinded, randomized, controlled, intra-individual study, involving participants with psoriasis vulgaris.
- Trial name
- NCT03025282
- Testing
- CD10367 3% Solution - Non-desquamated zone, CD10367 1% Solution - Non-desquamated zone, Betneval ointment - Non-desquamated zone
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Galderma R&D
Stable Plaque Psoriasis
A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis
This study is conducted to assess the efficacy and safety of LEO 90100 when used on the body for the treatment of stable plaque psoriasis in native adult Chinese subjects, compared to Daivobet® ointment.
- Trial name
- NCT05919082
- Testing
- LEO 90100, Daivobet® ointment
- Where
- 38 sites in China
- Volunteers
- 604 people
- Sponsor
- LEO Pharma
Palmoplantar Pustulosis
Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS)
Multicenter, open-label, single-arm, phase II, pilot study. The screening period was up to 4 weeks and treatment took place over 20 weeks per patient.
- Trial name
- APLANTUS (NCT04572997)
- Testing
- Apremilast
- Where
- 5 sites in Germany
- Volunteers
- 21 people
- Sponsor
- Kristian Reich
Psoriatic Arthritis
Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis
This study is to look at the preliminary efficacy and safety of 2 dose regimens of apremilast (20 mg twice a day and 40 mg once a day) versus placebo in patients with active psoriatic arthritis.
- Trial name
- NCT00456092
- Testing
- Apremilast
- Where
- 38 sites in Belgium, Canada and 3 more
- Volunteers
- 204 people
- Sponsor
- Amgen
Psoriatic Arthritis
A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis
This is a 52 week Phase 2b study designed to evaluate the efficacy at 16 weeks and to evaluate the safety and efficacy up to 1 year in subjects with active psoriatic arthritis.
- Trial name
- NCT03963401
- Testing
- PF-06700841
- Where
- 48 sites in Australia, Bulgaria and 9 more
- Volunteers
- 219 people
- Sponsor
- Pfizer
Plaque-type Psoriasis
Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis
The study will assess the safety and efficacy of intravenous (10mg/kg) and subcutaneous (300mg) secukinumab in moderate to severe chronic plaque-type psoriasis who are partial responders to secukinumab.
- Trial name
- STATURE (NCT01412944)
- Testing
- secukinumab 150mg, secukinumab 10mg/kg i.v. regimen
- Where
- 27 sites in United States, Austria and 6 more
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis, Psoriatic Arthritis
Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis
The primary objective of this study is to evaluate the effect of filgotinib on semen parameters in adult males with active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-Radiographical Axial Spondyloarthritis
- Trial name
- MANTA-RAy (NCT03926195)
- Testing
- Filgotinib, Standard of Care
- Where
- 71 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 109 people
- Sponsor
- Lakefront Biotherapeutics NV
Chronic Plaque Psoriasis
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis
This is a study to assess the long-term safety, tolerability, and efficacy of bimekizumab.
- Trial name
- NCT03230292
- Testing
- Bimekizumab
- Where
- 10 sites in United States, Australia and 2 more
- Volunteers
- 43 people
- Sponsor
- UCB Biopharma SRL
Plaque Psoriasis
Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
The purpose of this study was to determine if secukinumab is effective and safe in the treatment of plaque type psoriasis
- Trial name
- NCT03066609
- Testing
- Secukinumab 150 mg s.c., Secukinumab 300 mg s.c.
- Where
- 32 sites in China, Hungary and 4 more
- Volunteers
- 543 people
- Sponsor
- Novartis Pharmaceuticals